Celecoxib in Preventing Skin Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Fitzpatrick type I-IV skin
• •No history of photosensitivity (e.g., systemic or discoid lupus erythematosus, polymorphous light eruption, or photocontact dermatitis)
• •No history of abnormal tanning responses or other unusual reactions to natural or artificial light sources
• •Willing to wear sun-protective clothing and SPF 15-49 sunscreen
• •Willing and able to restrict the frequency of high ultraviolet-exposure activities (e.g., exposure to sunlight, tanning boxes, or other artificial light sources)
• •No history of keloid formation
• •PATIENT CHARACTERISTICS:
• •Age:
• •20 to 60
• •Performance status:
• •Not specified
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •WBC ≥ 3,500/mm\^3
• •Hemoglobin ≥ 12.0 g/dL
• •No bleeding disorder
• •Hepatic:
• •Bilirubin ≤ 20% above upper limit of normal (ULN)
• •AST and ALT ≤ 20% above ULN
• •No chronic or acute hepatic disease
• •Renal:
• •Creatinine ≤ 20% above ULN
• •No chronic or acute renal disease
• •Gastrointestinal:
• •No active gastrointestinal disease (e.g., inflammatory bowel disease)
• •No pancreatic disease
• •No esophageal, gastric, pyloric channel, or duodenal ulceration
• •Other:
• •No invasive cancer except nonmelanoma skin cancer cured by excision or stage I cervical cancer
• •No hypersensitivity or adverse reactions to NSAIDs, salicylates, cyclo-oxygenase-2 (COX-2) inhibitors, or sulfonamides
• •No condition that would preclude the use of NSAIDs
• •No clinically significant laboratory abnormalities
• •No medical or psychosocial condition that would preclude study participation
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile participants must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •No concurrent chemo-immunotherapy
• •Chemotherapy:
• •See Biologic therapy
• •At least 1 year since prior chemotherapy, including topical fluorouracil
• •Endocrine therapy:
• •At least 2 weeks since prior topical glucocorticoids
• •At least 30 days since prior systemic corticosteroids
• •No concurrent systemic glucocorticoids (inhaled corticosteroids allowed)
• •No concurrent topical corticosteroids
• •No concurrent hormonal therapy
• •Hormone replacement (e.g., estrogen or thyroid replacement) allowed
• •Radiotherapy:
• •No concurrent radiotherapy
• •Surgery:
• •Not specified
• •Other:
• •At least 14 days since prior aspirin (\> 100 mg/day) or other non-steroidal anti-inflammatory drugs (NSAIDs) taken at least 3 times per week
• •At least 2 weeks since prior topical alpha hydroxy acids (e.g., glycolic acid or lactic acid)
• •At least 6 months since prior oral retinoids (3 months for topical retinoids to the face)
• •At least 30 days since prior treatment for esophageal, gastric, pyloric channel, or duodenal ulceration
• •At least 30 days since prior investigational medication
• •No other concurrent investigational medication
• •No concurrent topical vitamin A derivatives and/or alpha hydroxy acids
• •No concurrent immunosuppressive drugs
• •No concurrent topical medication to the skin, including prescription and over-the-counter preparations (moisturizers and emollients allowed)
• •No concurrent lithium, fluconazole, or warfarin
• •No concurrent chronic NSAIDs (\> 3 times per week for \> 2 consecutive weeks per year)
• •Concurrent cardioprotective doses of aspirin (≤ 100 mg/day) allowed
• •Concurrent acetaminophen allowed
• •No concurrent green tea consumption of \> 2 cups per day